Improving Proton Pump Inhibitor Use in Adults in Ras Al Khaimah Through Pharmacist-Led Education and Intervention

What this Trial Is About

Researchers are evaluating whether a pharmacist-led educational program can reduce the inappropriate use of proton pump inhibitors PPIs among adults aged 18 years and older with potentially unnecessary PPI prescriptions in Ras Al Khaimah. The study aims to see if this intervention can lower PPI use, improve patients quality of life, and reduce healthcare costs by comparing the intervention group to those receiving usual care. The study is interventional and involves education for both patients and physicians to promote evidence-based deprescribing practices. The study has two groups one receives a pharmacist-led educational intervention including brochures, videos, decision aids, and deprescribing algorithms aimed at encouraging appropriate PPI use. The other group continues with standard care without any pharmacist intervention during the six-month period. Physicians in the intervention group also receive educational materials and guidance to support deprescribing. After six months, educational materials will be offered to the control group. Participants will be followed for six months to track changes in PPI use, symptoms related to gastroesophageal reflux disease, quality of life, medication counts, potential adverse effects, attitudes toward deprescribing, and healthcare costs. Assessments include questionnaires such as the Gastroesophageal Reflux Disease Impact Scale and EuroQol 5-Dimension 5-Level survey. Researchers will monitor if patients stop or reduce PPI doses and evaluate cost-effectiveness and quality-adjusted life years gained over the study period.

RAK-PRIDE: Optimizing Proton Pump Inhibitor Use Through Education and Intervention